世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

カスタム抗体市場：サービス別（開発、精製、標識）、タイプ別（モノクローナル、組み換え）、ソース別（ウサギ、マウス）、用途別（研究、治療）、適応症別（腫瘍学、免疫学）、エンドユーザー別（バイオファーマ、CROs） - 2028年までの世界予測


Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) - Global Forecast to 2028

カスタム抗体の世界市場規模は、2023年の5億4800万米ドルから2028年には8億6000万米ドルに達し、予測期間中のCAGRは9.4%と予測されています。ADC開発のための投資の増加や、カスタム抗体の構造ベースドラッグデザ... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年2月28日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		278 352 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

カスタム抗体の世界市場規模は、2023年の5億4800万米ドルから2028年には8億6000万米ドルに達し、予測期間中のCAGRは9.4%と予測されています。ADC開発のための投資の増加や、カスタム抗体の構造ベースドラッグデザインと治療薬mAbsの研究の高まりなどの要因が、市場の成長を加速させています。

"組み換え抗体セグメントは、2023-2028年の予測期間中に最も高いCAGRで成長しそうです。"
カスタム抗体市場は、タイプ別に、モノクローナル抗体、ポリクローナル抗体、リコンビナント抗体、その他に分類されます。予測期間中に最も高いCAGRで成長すると予測されているのは、リコンビナント抗体セグメントです。この成長は、組換え抗体が提供する低い免疫原性と研究の再現性の向上に起因しています。これは、セグメント別の成長にプラスの影響を与えると考えられます。

"2023年はマウスソースが圧倒的なシェアを占めると予想される"
ソースに基づき、市場はマウス、ウサギ、その他に区分されます。マウスセグメントは、研究目的のmAbs生産においてマウスが従来から好ましい宿主であるという要因から、予測期間中により速いペースで成長すると予想されます。

"2022年、研究用途分野が圧倒的なシェアを占める"
用途に基づき、カスタム抗体市場は研究用途と治療用途に区分される。カスタム抗体市場では、研究用途分野が圧倒的なシェアを占めています。研究および創薬・開発におけるカスタム抗体の採用は、市場成長を予測させる主要な要因の1つである

"2023年～2028年の予測期間において、オンコロジー分野が最も高いCAGRで成長しそうです。"
カスタム抗体市場は、適応症に基づき、オンコロジー、感染症、免疫学、神経生物学、心血管疾患、その他に区分される。2022年のカスタム抗体市場では、オンコロジー適応症分野が圧倒的なシェアを占めています。がん治療におけるmAbとカスタム抗体の使用の増加は、市場成長を予測する主要な要因の1つである。
"アジア太平洋地域はより速いペースで成長すると思われる。"
カスタム抗体市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに分けられます。2022年、北米はカスタム抗体市場の圧倒的なシェアを占めています。同地域の優位性は、カスタム抗体の継続的な研究活動と相まって、同地域における支配的かつ主要な市場プレイヤーの存在など、さまざまな要因に起因しています。アジア太平洋地域は、個別化治療に対する意識の高まり、同地域における抗体開発のための政府による研究イニシアチブの高まり、カスタム抗体市場における新規参入企業の出現など、さまざまな要因により、より速いペースで成長すると思われます。
本レポートのために実施した一次インタビューは、以下のように分類されます：

- 回答者別供給側：60％、需要側：40
- 役職別（サプライサイド）：マネージャー45％、CXO・ディレクター25％、エグゼクティブ15％、その他15.0
- 地域別北米：40％、欧州：25％、アジア太平洋：20％、中南米：10％、中近東・アフリカ：5％。
レポート掲載企業の一覧です：
- サーモフィッシャーサイエンティフィック（米国）
- ジェンスクリプト（中国）
- Abcam plc.(英国)
- Cell Signaling Technology, Inc（米国）
- バイオ・ラッド・ラボラトリーズ・インク（米国）
- メルクKGaA（ドイツ）
- アジレント・テクノロジー株式会社（ドイツ）
- パーキンエルマー社(米国)
- ロックランド イムノケミカルズ インク（米国）
- プロマブ・バイオテクノロジーズ・インク（米国）
- Innovagen AB（スウェーデン）
- オリジェネ・テクノロジーズ（米国）
- バイオテクネ（米国）
- クリエイティブ・ダイアグノスティックス（米国）
- Sino Biological, Inc（中国）
- レイバイオテック・ライフ社（米国）
- Abbiotec, Inc（米国）
- プロサイ（米国）
- ボスター・バイオロジカル・テクノロジー（米国）
- CUSABIO Technology LLC (米国)
- バイオイントロン（中国）
- カネカ・ユーロジェンテックS.A.(ベルギー)
- クリエイティブ・バイオラボズ（米国）
- エンビゴ（米国）
- Imgenex India Pvt. Ltd（インド）。
調査対象です：
本レポートは、カスタム抗体市場の詳細な情報を提供します。サービス、タイプ、ソース、アプリケーション、適応症、エンドユーザー、地域などの異なるセグメントにおける市場規模および今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの会社概要、最近の開発状況、主要な市場戦略とともに、詳細な競合分析も行っています。

レポートを購入する主な利点
本レポートは、カスタム抗体市場全体とそのサブセグメントにおける収益数の最も近い近似値を提供することで、市場リーダー/新規参入者の助けとなります。また、利害関係者が競争環境をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

ページTOPに戻る


目次

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 30
1.7.1 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 33
FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS 34
2.2 MARKET ESTIMATION METHODOLOGY 34
2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022) 35
FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): CUSTOM ANTIBODY MARKET 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY 36
2.3 DATA TRIANGULATION APPROACH 37
FIGURE 5 DATA TRIANGULATION METHODOLOGY 37
2.4 GROWTH RATE ASSUMPTIONS 38
2.5 GROWTH FORECAST 38
FIGURE 6 GROWTH RATE ANALYSIS 38
2.6 RISK ASSESSMENT 39
2.7 INSIGHTS FROM PRIMARY EXPERTS 39
2.8 CUSTOM ANTIBODY MARKET: RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41
3 EXECUTIVE SUMMARY 42
FIGURE 7 CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028 42
FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2023 VS. 2028 43
FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2023 VS. 2028 44
FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY APPLICATION, 2023 VS. 2028 44
FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY INDICATION, 2023 VS. 2028 45
FIGURE 12 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 VS. 2028 46
FIGURE 13 CUSTOM ANTIBODY MARKET: GEOGRAPHICAL SNAPSHOT 47
4 PREMIUM INSIGHTS 48
4.1 CUSTOM ANTIBODY MARKET OVERVIEW 48
FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 48
4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2022) 49
FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2022) 49
FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 4 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising research activities and funding investments for antibody development 52
5.2.1.2 Growing use of custom antibodies in precision medicine 53
5.2.1.3 Use of antibodies in biomarker identification and validation 53
5.2.1.4 Quality concerns over catalog antibodies 54
5.2.2 RESTRAINTS 54
5.2.2.1 High costs and complexities associated with antibody development 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Emerging markets 55
5.2.3.2 Rising therapeutic applications for mAbs 55
FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016−2022) 56
5.2.4 CHALLENGES 56
5.2.4.1 Challenges associated with immunization of host animals 56
5.2.4.2 Presence of alternative antibodies 57
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 20 CUSTOM ANTIBODY MARKET: VALUE-CHAIN ANALYSIS 57
5.4 ECOSYSTEM ANALYSIS 59
FIGURE 21 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS 59
5.4.1 ROLE IN ECOSYSTEM 59
5.5 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.5.1 THREAT OF NEW ENTRANTS 60
5.5.2 THREAT OF SUBSTITUTES 60
5.5.3 BARGAINING POWER OF SUPPLIERS 61
5.5.4 BARGAINING POWER OF BUYERS 61
5.5.5 DEGREE OF COMPETITION 61
5.6 PATENT ANALYSIS 62
FIGURE 22 CUSTOM ANTIBODY MARKET: PATENT ANALYSIS 62
5.7 PRICING ANALYSIS 62
5.7.1 AVERAGE SELLING PRICE TREND 62
5.7.2 INDICATIVE PRICING ANALYSIS 63
TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT 63
TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC. 63
5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION 63
TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA 63
TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US 64
5.8 TECHNOLOGICAL ANALYSIS 64
5.8.1 CUSTOM ANTIBODY SERVICES 64
5.9 REGULATORY LANDSCAPE 65
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
5.10 KEY CONFERENCES & EVENTS IN 2023 66
TABLE 11 CUSTOM ANTIBODY MARKET: DETAILED LIST OF CONFERENCES & EVENTS 66
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 67
FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS 67
FIGURE 24 CUSTOM ANTIBODY MARKET: KEY BUYING CRITERIA FOR END USERS 67
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 25 REVENUE SHIFT AND NEW REVENUE 68
6 CUSTOM ANTIBODY MARKET, BY SERVICE 69
6.1 INTRODUCTION 70
TABLE 12 CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 70
6.2 ANTIBODY DEVELOPMENT 70
TABLE 13 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 71
TABLE 14 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 71
TABLE 15 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 16 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 18 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.2.1 ANTIBODY CHARACTERIZATION 73
6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market 73
TABLE 19 CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 20 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 21 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 22 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 23 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.2 ANTIGEN PREPARATION 76
6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth 76
TABLE 24 CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 25 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 26 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 28 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 79
6.2.3.1 Rising demand for therapeutic antibodies to drive market 79
TABLE 29 CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 31 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 33 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.3 ANTIBODY PRODUCTION & PURIFICATION 82
6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET 82
TABLE 34 CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 36 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 37 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 38 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.4 ANTIBODY FRAGMENTATION & LABELING 85
6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH 85
TABLE 39 CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021–2028 (USD MILLION) 86
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 41 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 42 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 43 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 88
7 CUSTOM ANTIBODY MARKET, BY TYPE 89
7.1 INTRODUCTION 90
TABLE 44 CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 90
7.2 MONOCLONAL ANTIBODIES 90
7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET 90
TABLE 45 CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 46 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 47 EUROPE: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 48 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 49 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 93
7.3 POLYCLONAL ANTIBODIES 93
7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE 93
TABLE 50 CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 52 EUROPE: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.4 RECOMBINANT ANTIBODIES 96
7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET 96
TABLE 55 CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 56 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, 2021–2028 (USD MILLION) 98
TABLE 58 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 59 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.5 OTHER CUSTOM ANTIBODIES 99
TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
8 CUSTOM ANTIBODY MARKET, BY SOURCE 102
8.1 INTRODUCTION 103
TABLE 65 CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 103
8.2 MICE 103
8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE 103
TABLE 66 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 67 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 68 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 69 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 70 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
8.3 RABBITS 105
8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET 105
TABLE 71 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 72 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 73 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 74 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 75 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 108
8.4 OTHER SOURCES 108
TABLE 76 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 77 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 78 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 79 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 80 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
9 CUSTOM ANTIBODY MARKET, BY APPLICATION 111
9.1 INTRODUCTION 112
TABLE 81 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
9.2 RESEARCH 112
9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET 112
TABLE 82 CUSTOM ANTIBODY MARKET FOR RESEARCH, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 83 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 84 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 85 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 86 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 115
9.3 THERAPEUTICS 115
9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET 115
TABLE 87 CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 88 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 89 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 90 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 91 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 118
10 CUSTOM ANTIBODY MARKET, BY INDICATION 119
10.1 INTRODUCTION 120
TABLE 92 CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 120
10.2 ONCOLOGY 120
10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET 120
TABLE 93 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 94 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 95 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 97 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 123
10.3 INFECTIOUS DISEASES 123
10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET 123
TABLE 98 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 99 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 100 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 102 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
10.4 IMMUNOLOGY 126
10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET 126
TABLE 103 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 104 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 105 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 106 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 107 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
10.5 NEUROBIOLOGY 128
10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET 128
TABLE 108 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
10.6 CARDIOVASCULAR DISEASES 130
10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET 130
TABLE 113 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 114 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 115 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 116 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 117 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 133
10.7 OTHER INDICATIONS 133
TABLE 118 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 119 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 120 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 121 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 122 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
11 CUSTOM ANTIBODY MARKET, BY END USER 136
11.1 INTRODUCTION 137
TABLE 123 CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 137
TABLE 124 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 125 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 126 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 128 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 139
11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET 139
TABLE 129 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 130 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 131 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 132 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 133 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 142
11.3 ACADEMIC & RESEARCH INSTITUTES 142
11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET 142
TABLE 134 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 135 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 136 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 137 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 138 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 145
11.4 CONTRACT RESEARCH ORGANIZATIONS 145
11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH 145
TABLE 139 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 140 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 141 EUROPE: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 142 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 143 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 148
12 CUSTOM ANTIBODY MARKET, BY REGION 149
12.1 INTRODUCTION 150
TABLE 144 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 150
12.2 NORTH AMERICA 151
FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT 152
TABLE 145 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 153
TABLE 147 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 148 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 149 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 154
TABLE 150 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 154
TABLE 151 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 152 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 155
12.2.1 US 155
12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market 155
TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 156
TABLE 154 US: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 155 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 156 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 157
TABLE 157 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 158 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 158
TABLE 159 US: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 158
12.2.2 CANADA 158
12.2.2.1 Increasing genomic research to fuel market uptake 158
TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 159
TABLE 161 CANADA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 162 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 163 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 160
TABLE 164 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 165 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 161
TABLE 166 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 161
12.2.3 NORTH AMERICA: RECESSION IMPACT 162
12.3 EUROPE 162
TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 163
TABLE 169 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 170 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 171 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 164
TABLE 172 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 173 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 165
TABLE 174 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 165
12.3.1 GERMANY 165
12.3.1.1 High investments in development of ADCs to drive market 165
TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 166
TABLE 176 GERMANY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 177 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 178 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 167
TABLE 179 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 167
TABLE 180 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 167
TABLE 181 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 168
12.3.2 UK 168
12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market 168
TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 169
TABLE 183 UK: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 184 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 185 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 170
TABLE 186 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 187 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 170
TABLE 188 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 171
12.3.3 FRANCE 171
12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth 171
TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 172
TABLE 190 FRANCE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 191 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 192 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 173
TABLE 193 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 194 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 173
TABLE 195 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.3.4 ITALY 174
12.3.4.1 Increasing research activities in proteomics & genomics to drive market 174
TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 175
TABLE 197 ITALY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 198 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 199 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 176
TABLE 200 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 201 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 176
TABLE 202 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.3.5 SPAIN 177
12.3.5.1 Growing focus on advancements in personalized medicine to support market growth 177
TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 178
TABLE 204 SPAIN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 205 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 206 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 179
TABLE 207 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 208 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
TABLE 209 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
12.3.6 REST OF EUROPE 180
TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 180
TABLE 211 REST OF EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 212 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 213 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 181
TABLE 214 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 215 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 182
TABLE 216 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3.7 EUROPE: RECESSION IMPACT 183

　

ページTOPに戻る


　

Summary

The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4% during the forecast period. Factors such as increasing investment for the development of ADCs and rising research in structure-based drug design and therapeutics mAbs of custom antibody, are driving the market growth at a faster pace.

“The recombinant antibodies segment is likely to grow at highest CAGR during the forecast period of 2023-2028.”
On the basis of type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. The recombinant antibodies segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to low immunogenicity and increased research reproducibility offered by recombinant antibodies. This is likely to have a positive impact on segmental growth.

“The mice source is expected to hold a dominant share in 2023.”
Based on the source, the market is segmented into mice, rabbits, and others. The mice segment is expected to grow at a faster pace during the forecast period due to factors that mice are conventionally preferred hosts for mAbs production for research purposes.

“In 2022, the research applications segment held a dominant share.”
Based on application, the custom antibody market is segmented into research and therapeutic applications. The research applications segment held a dominant share of the custom antibody market. Adoption of custom antibody in research and drug discovery & development is one of the major factors anticipated to project the market growth

“The oncology segment is likely to grow at highest CAGR during the forecast period of 2023-2028.”
Based on indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and others. The oncology indication segment held a dominant share of the custom antibody market, in 2022. The growing use of mAbs and custom antibody in cancer treatment is one of the major factor anticipated to project market growth.
“Asia Pacific region is likely to grow at faster pace.”
The custom antibody market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of custom antibody market. The dominance of the region is attributable to various factors such as the presence of dominant and key market players in the region coupled with the ongoing research activities of custom antibody. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising research initiatives undertaken by the government for antibody development in the region, and the emergence of new market players in the custom antibody market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60%, and Demand Side - 40%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific (US)
• GenScript (China)
• Abcam plc. (UK)
• Cell Signaling Technology, Inc (US)
• Bio-Rad Laboratories, Inc (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc (Germany)
• PerkinElmer, Inc (US)
• Rockland Immunochemicals, Inc (US)
• ProMab Biotechnologies, Inc (US)
• Innovagen AB (Sweden)
• OriGene Technologies (US)
• Bio-Techne (US)
• Creative Diagnostics (US)
• Sino Biological, Inc (China)
• RayBiotech Life, Inc (US)
• Abbiotec, Inc (US)
• ProSci (US)
• Boster Biological Technology (US)
• CUSABIO Technology LLC (US)
• Biointron (China)
• Kaneka Eurogentech S.A. (Belgium)
• Creative Biolabs (US)
• Envigo (US)
• Imgenex India Pvt. Ltd (India).
Research Coverage:
This report provides a detailed picture of the custom antibody market. It aims at estimating the size and future growth potential of the market across different segments, such as service, type, source, application, indication, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 30
1.7.1 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 33
FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS 34
2.2 MARKET ESTIMATION METHODOLOGY 34
2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022) 35
FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): CUSTOM ANTIBODY MARKET 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY 36
2.3 DATA TRIANGULATION APPROACH 37
FIGURE 5 DATA TRIANGULATION METHODOLOGY 37
2.4 GROWTH RATE ASSUMPTIONS 38
2.5 GROWTH FORECAST 38
FIGURE 6 GROWTH RATE ANALYSIS 38
2.6 RISK ASSESSMENT 39
2.7 INSIGHTS FROM PRIMARY EXPERTS 39
2.8 CUSTOM ANTIBODY MARKET: RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41
3 EXECUTIVE SUMMARY 42
FIGURE 7 CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028 42
FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2023 VS. 2028 43
FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2023 VS. 2028 44
FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY APPLICATION, 2023 VS. 2028 44
FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY INDICATION, 2023 VS. 2028 45
FIGURE 12 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 VS. 2028 46
FIGURE 13 CUSTOM ANTIBODY MARKET: GEOGRAPHICAL SNAPSHOT 47
4 PREMIUM INSIGHTS 48
4.1 CUSTOM ANTIBODY MARKET OVERVIEW 48
FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 48
4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2022) 49
FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2022) 49
FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 4 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising research activities and funding investments for antibody development 52
5.2.1.2 Growing use of custom antibodies in precision medicine 53
5.2.1.3 Use of antibodies in biomarker identification and validation 53
5.2.1.4 Quality concerns over catalog antibodies 54
5.2.2 RESTRAINTS 54
5.2.2.1 High costs and complexities associated with antibody development 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Emerging markets 55
5.2.3.2 Rising therapeutic applications for mAbs 55
FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016−2022) 56
5.2.4 CHALLENGES 56
5.2.4.1 Challenges associated with immunization of host animals 56
5.2.4.2 Presence of alternative antibodies 57
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 20 CUSTOM ANTIBODY MARKET: VALUE-CHAIN ANALYSIS 57
5.4 ECOSYSTEM ANALYSIS 59
FIGURE 21 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS 59
5.4.1 ROLE IN ECOSYSTEM 59
5.5 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.5.1 THREAT OF NEW ENTRANTS 60
5.5.2 THREAT OF SUBSTITUTES 60
5.5.3 BARGAINING POWER OF SUPPLIERS 61
5.5.4 BARGAINING POWER OF BUYERS 61
5.5.5 DEGREE OF COMPETITION 61
5.6 PATENT ANALYSIS 62
FIGURE 22 CUSTOM ANTIBODY MARKET: PATENT ANALYSIS 62
5.7 PRICING ANALYSIS 62
5.7.1 AVERAGE SELLING PRICE TREND 62
5.7.2 INDICATIVE PRICING ANALYSIS 63
TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT 63
TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC. 63
5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION 63
TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA 63
TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US 64
5.8 TECHNOLOGICAL ANALYSIS 64
5.8.1 CUSTOM ANTIBODY SERVICES 64
5.9 REGULATORY LANDSCAPE 65
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
5.10 KEY CONFERENCES & EVENTS IN 2023 66
TABLE 11 CUSTOM ANTIBODY MARKET: DETAILED LIST OF CONFERENCES & EVENTS 66
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 67
FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS 67
FIGURE 24 CUSTOM ANTIBODY MARKET: KEY BUYING CRITERIA FOR END USERS 67
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 25 REVENUE SHIFT AND NEW REVENUE 68
6 CUSTOM ANTIBODY MARKET, BY SERVICE 69
6.1 INTRODUCTION 70
TABLE 12 CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 70
6.2 ANTIBODY DEVELOPMENT 70
TABLE 13 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 71
TABLE 14 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 71
TABLE 15 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 16 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 18 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.2.1 ANTIBODY CHARACTERIZATION 73
6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market 73
TABLE 19 CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 20 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 21 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 22 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 23 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.2 ANTIGEN PREPARATION 76
6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth 76
TABLE 24 CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 25 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 26 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 28 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 79
6.2.3.1 Rising demand for therapeutic antibodies to drive market 79
TABLE 29 CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 31 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 33 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.3 ANTIBODY PRODUCTION & PURIFICATION 82
6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET 82
TABLE 34 CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 36 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 37 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 38 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.4 ANTIBODY FRAGMENTATION & LABELING 85
6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH 85
TABLE 39 CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021–2028 (USD MILLION) 86
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 41 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 42 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 43 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 88
7 CUSTOM ANTIBODY MARKET, BY TYPE 89
7.1 INTRODUCTION 90
TABLE 44 CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 90
7.2 MONOCLONAL ANTIBODIES 90
7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET 90
TABLE 45 CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 46 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 47 EUROPE: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 48 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 49 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 93
7.3 POLYCLONAL ANTIBODIES 93
7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE 93
TABLE 50 CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 52 EUROPE: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.4 RECOMBINANT ANTIBODIES 96
7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET 96
TABLE 55 CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 56 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, 2021–2028 (USD MILLION) 98
TABLE 58 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 59 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.5 OTHER CUSTOM ANTIBODIES 99
TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
8 CUSTOM ANTIBODY MARKET, BY SOURCE 102
8.1 INTRODUCTION 103
TABLE 65 CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 103
8.2 MICE 103
8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE 103
TABLE 66 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 67 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 68 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 69 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 70 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
8.3 RABBITS 105
8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET 105
TABLE 71 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 72 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 73 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 74 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 75 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 108
8.4 OTHER SOURCES 108
TABLE 76 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 77 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 78 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 79 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 80 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
9 CUSTOM ANTIBODY MARKET, BY APPLICATION 111
9.1 INTRODUCTION 112
TABLE 81 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
9.2 RESEARCH 112
9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET 112
TABLE 82 CUSTOM ANTIBODY MARKET FOR RESEARCH, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 83 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 84 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 85 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 86 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 115
9.3 THERAPEUTICS 115
9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET 115
TABLE 87 CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 88 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 89 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 90 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 91 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 118
10 CUSTOM ANTIBODY MARKET, BY INDICATION 119
10.1 INTRODUCTION 120
TABLE 92 CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 120
10.2 ONCOLOGY 120
10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET 120
TABLE 93 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 94 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 95 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 97 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 123
10.3 INFECTIOUS DISEASES 123
10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET 123
TABLE 98 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 99 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 100 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 102 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
10.4 IMMUNOLOGY 126
10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET 126
TABLE 103 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 104 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 105 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 106 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 107 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
10.5 NEUROBIOLOGY 128
10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET 128
TABLE 108 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
10.6 CARDIOVASCULAR DISEASES 130
10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET 130
TABLE 113 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 114 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 115 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 116 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 117 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 133
10.7 OTHER INDICATIONS 133
TABLE 118 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 119 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 120 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 121 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 122 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
11 CUSTOM ANTIBODY MARKET, BY END USER 136
11.1 INTRODUCTION 137
TABLE 123 CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 137
TABLE 124 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 125 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 126 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 128 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 139
11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET 139
TABLE 129 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 130 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 131 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 132 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 133 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 142
11.3 ACADEMIC & RESEARCH INSTITUTES 142
11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET 142
TABLE 134 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 135 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 136 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 137 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 138 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 145
11.4 CONTRACT RESEARCH ORGANIZATIONS 145
11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH 145
TABLE 139 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 140 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 141 EUROPE: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 142 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 143 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 148
12 CUSTOM ANTIBODY MARKET, BY REGION 149
12.1 INTRODUCTION 150
TABLE 144 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 150
12.2 NORTH AMERICA 151
FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT 152
TABLE 145 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 153
TABLE 147 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 148 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 149 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 154
TABLE 150 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 154
TABLE 151 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 152 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 155
12.2.1 US 155
12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market 155
TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 156
TABLE 154 US: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 155 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 156 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 157
TABLE 157 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 158 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 158
TABLE 159 US: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 158
12.2.2 CANADA 158
12.2.2.1 Increasing genomic research to fuel market uptake 158
TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 159
TABLE 161 CANADA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 162 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 163 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 160
TABLE 164 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 165 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 161
TABLE 166 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 161
12.2.3 NORTH AMERICA: RECESSION IMPACT 162
12.3 EUROPE 162
TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 163
TABLE 169 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 170 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 171 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 164
TABLE 172 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 173 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 165
TABLE 174 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 165
12.3.1 GERMANY 165
12.3.1.1 High investments in development of ADCs to drive market 165
TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 166
TABLE 176 GERMANY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 177 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 178 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 167
TABLE 179 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 167
TABLE 180 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 167
TABLE 181 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 168
12.3.2 UK 168
12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market 168
TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 169
TABLE 183 UK: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 184 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 185 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 170
TABLE 186 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 187 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 170
TABLE 188 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 171
12.3.3 FRANCE 171
12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth 171
TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 172
TABLE 190 FRANCE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 191 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 192 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 173
TABLE 193 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 194 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 173
TABLE 195 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.3.4 ITALY 174
12.3.4.1 Increasing research activities in proteomics & genomics to drive market 174
TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 175
TABLE 197 ITALY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 198 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 199 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 176
TABLE 200 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 201 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 176
TABLE 202 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.3.5 SPAIN 177
12.3.5.1 Growing focus on advancements in personalized medicine to support market growth 177
TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 178
TABLE 204 SPAIN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 205 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 206 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 179
TABLE 207 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 208 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
TABLE 209 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
12.3.6 REST OF EUROPE 180
TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 180
TABLE 211 REST OF EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 212 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 213 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 181
TABLE 214 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 215 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 182
TABLE 216 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3.7 EUROPE: RECESSION IMPACT 183

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.